CME: Glaucoma: optimizing pharmacotherapeutic management strategies
Cost: FreeView Offer chevron_right
Glaucoma, a heterogeneous disease leading to progressive damage to the optic nerve, causes irreversible vision loss and affects up to six million people in the U.S., and just as many worldwide have glaucoma-related bilateral blindness. The prevalence of glaucoma is increasing, and more than 100 million people across the globe will have glaucoma by 2040. Approximately half of all individuals with glaucoma are unaware of their condition due to the asymptomatic nature of the disease. Although the incidence of glaucoma-related blindness has decreased over the last 20 years thanks to effective management strategies, 13% to 40% of people with glaucoma still develop unilateral or bilateral blindness, typically at a rate of 1.1% per year.
By the end of the session the participant will be able to:
- Individualize intraocular pressure targets based on known risk factors and patient-specific characteristics, and optimize assessment of intraocular pressure profiles to readily identify peaks and fluctuations
- Identify first-line pharmacotherapies, laser therapies, and glaucoma implants for lowering intraocular pressure, and select appropriate monotherapies and combination therapies for patients
- Discuss present and emerging pharmacotherapies currently in clinical development and their mechanisms of action, and apply those therapies to patient cases
- Describe barriers to care in the treatment of patients with glaucoma and what clinicians may do to aide patients in circumventing them
Healthcare professionals (HCPs) including: comprehensive ophthalmologists and retinal specialists; physician assistants and nurse practitioners who practice in ophthalmology; and any other HCPs with an interest in or who clinically encounter patients with glaucoma.